Ireland
--:--IST
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Porto
Clinical trial register · Portugal

Clinical Trials in Porto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1100 matching records held by the registry are in this view. Synced 03 Oct 2026, 03:16 UTC
1100
Studies in scope
all four open statuses
535
Recruiting now
open to new participants
284
Lead sponsors
across recruiting studies
Top sites
Lisbon 32 Porto 30 Braga 16 Vila Nova de Gaia 10 Coimbra 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universidade do Porto33 Janssen Research & Development, LLC30 AbbVie26 AstraZeneca26 Hoffmann-La Roche24 Clear sponsor filter
Site location
Lisbon32 Porto30 Braga16 Vila Nova de Gaia10 Coimbra9
All 24 locations
Target enrolment
to

Trials with a site in Porto

30 of 1100 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634Multiple Myeloma
DrugsRamantamig·Tocilizumab
Janssen Research & Development, LLC
Phase 2
230
Braga, Lisbon, Porto
2026-06-30
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
Almada, Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia
2026-03-05
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Lisbon, Portimão, Porto, Vila Nova de Gaia
2025-12-03
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Braga, Guimarães, Lisbon, Loures, Porto
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Braga, Guimarães, Lisbon, Loures, Porto, Viana do Castelo
2025-10-01
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Lisbon, Porto
2025-06-04
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Guimarães, Leiria, Lisbon, Porto
2025-04-15
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2024-12-16
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Braga, Porto
2024-10-29
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Coimbra, Porto
2024-09-19
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
752
Braga, Leiria, Lisbon, Loures, Ponta Delgada, Porto, Touguinho
2024-07-25
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
120
Braga, Lisbon, Porto
2024-03-13
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
112
Lisbon, Porto
2024-01-19
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Almada, Braga, Lisbon, Porto, Vila Nova de Gaia
2023-03-29
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Braga, Coimbra, Covilha, Guimarães, Lisbon, Porto, Pragal, Santa Maria da Feira
2023-02-15
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Braga, Lisbon, Porto
2022-10-25
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Almada, Braga, Porto
2022-09-23
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Lisbon, Portimão, Porto, Santa Maria da Feira
2022-07-22
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
776
Lisbon, Loures, Porto
2021-11-17
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Braga, Guarda, Lisbon, Ponte de Lima, Porto
2021-08-30
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
Lisbon, Porto
2021-08-19
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 2
220
Almada, Aveiro, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia, Vila Real
2020-12-18
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin
Janssen Research & Development, LLC
Phase 3
518
Almada, Coimbra, Lisbon, Porto
2020-12-07
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
Lisbon, Porto, Vila Nova de Gaia
2020-10-13
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Lisbon, Porto
2020-09-30
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
DrugGuselkumab
Janssen Research & Development, LLC
Phase 2/3
1,064
Coimbra, Porto, Santa Maria da Feira, Viseu
2019-09-26
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
DrugsNiraparib·Abiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 3
765
Coimbra, Lisbon, Porto
2019-01-25
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Braga, Coimbra, Guimarães, Portimão, Porto, Santa Maria da Feira
2018-04-13
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
629
Lisbon, Porto
2018-03-23
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Lisbon, Porto
2013-09-09
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/porto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,100 studies in total at the last sync on 03 Oct 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Porto that also match the filters currently applied.

How many clinical trials are recruiting in Porto?

13 of the 30 studies on this page are recruiting new participants as of the 03 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Porto), 30 studies
PhaseStudiesRecruitingShare
Phase 320866.7%
Phase 2/35316.7%
Phase 24213.3%
Phase 4103.3%

Most active sponsors

Lead sponsors with the most studies (Porto)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC3013
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.